IDT Australia Ltd (ASX: IDT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

IDT Australia Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $65.96 million
P/E Ratio 136.99
Dividend Yield N/A
Shares Outstanding 239.86 million
Earnings per share 0.002
Dividend per share N/A
Year To Date Return 48.65%
Earnings Yield 0.73%
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

IDT ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About IDT Australia Ltd

IDT Australia Ltd produces, develops, and supplies pharmaceutical products. It is engaged in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company is involved in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging, and pharmacy services.

IDT Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
11 Jun 2021 $0.28 $-0.01 -3.57% 626,904 $0.29 $0.29 $0.25
10 Jun 2021 $0.28 $0.00 0.00% 46,934 $0.27 $0.28 $0.27
09 Jun 2021 $0.29 $-0.01 -3.39% 428,026 $0.30 $0.30 $0.27
08 Jun 2021 $0.30 $-0.01 -3.33% 91,225 $0.30 $0.30 $0.29
07 Jun 2021 $0.30 $-0.02 -6.25% 290,600 $0.33 $0.33 $0.30
04 Jun 2021 $0.32 $0.01 3.23% 31,180 $0.33 $0.33 $0.32
03 Jun 2021 $0.31 $-0.02 -6.15% 96,097 $0.32 $0.32 $0.31
02 Jun 2021 $0.33 $-0.01 -2.99% 44,713 $0.32 $0.33 $0.32
01 Jun 2021 $0.34 $0.01 3.03% 568,231 $0.34 $0.34 $0.33
31 May 2021 $0.33 $0.00 0.00% 399,555 $0.34 $0.34 $0.31
28 May 2021 $0.33 $-0.01 -2.94% 75,315 $0.35 $0.35 $0.33
27 May 2021 $0.34 $0.01 3.03% 311,175 $0.34 $0.35 $0.33
26 May 2021 $0.33 $0.03 9.84% 315,798 $0.31 $0.34 $0.31
25 May 2021 $0.31 $0.02 6.90% 297,820 $0.29 $0.31 $0.29
24 May 2021 $0.29 $-0.01 -3.33% 585,341 $0.30 $0.30 $0.28
21 May 2021 $0.30 $0.02 7.02% 1,076,492 $0.30 $0.33 $0.28
20 May 2021 $0.29 $-0.03 -9.68% 509,902 $0.32 $0.32 $0.28
19 May 2021 $0.31 $-0.01 -3.17% 59,663 $0.32 $0.32 $0.31
18 May 2021 $0.32 $0.00 0.00% 62,291 $0.32 $0.32 $0.31
17 May 2021 $0.32 $-0.01 -3.08% 129,233 $0.32 $0.32 $0.31

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
15 Oct 2020 Michael Kotsanis Buy 65 $10,400
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Alan David Fisher Non-Executive DirectorNon-Executive Chairman Jun 2015
Mr Fisher has experience in restoring and enhancing shareholder value. He spent 24 years at global accounting firm Coopers & Lybrand where he grew the Melbourne Corporate Finance Division. Following this tenure, he was doing his own corporate advisory business specialising in M&A, advice, business restructurings and capital raisings. He is currently a Non-Executive Chair Centrepoint Alliance Ltd, Non-Executive Director and Chair of Audit and Risk Committees of Bionomics Ltd, Thorney Technologies Ltd and Simavita Ltd. He is a member the Risk Committee.
Mr Michael John Kotsanis Non-Executive Director Mar 2020
Mr Kotsanis has over 30 years of operational experience in the global pharmaceutical industry. He was formerly the Chief Commercial Officer and a Board Member of Synthon Holding BV, a position he held for four years. Prior to Synthon, he served as President, Europe, Middle East and Africa, for Hospira. At Hospira he had served as President, Asia Pacific from 2002 and at Mayne he held responsibility for commercial activities of the pharmaceutical business in Australia and New Zealand. He was formerly a Board Member of the European Generics Association and a Director of the Generic Medicines Industry of Australia. He is currently a director of Acrux Ltd. He is a member of the Risk Committee.
Mr Hugh Nigel Burrill Non-Executive Director Oct 2015
Mr Burrill was formerly Corporate Vice President, Global Pharma Research & Development, Hospira Inc where he was part of overall pipeline portfolio management, and research and development of specialty pharmaceuticals. Prior to this he held senior international roles within Hospira Inc and the original Mayne Pharma Ltd and currently provides consulting services in pharmaceutical management, product development, regulatory affairs and intellectual property. Formerly, he was also a Non-Executive Director and Deputy Chair Nova Aerospace Pty Ltd. He is a Chairperson of the Risk Committee.
Ms Maria (Mary) Elisabeth Sontrop Non-Executive Director Mar 2017
Ms Sontrop has experience in the biopharmaceutical sector across manufacturing operations, quality and business integration. She has held executive roles at CSL Limited where she participated in international acquisitions, turned around unprofitable manufacturing operations. As head of CSL's Australia and New Zealand pharmaceutical business she and her team delivered the human papilloma virus immunisation programs and obtained FDA approval to manufacture and export seasonal and pandemic influenza vaccines.
Dr David Sparling Joint Company SecretaryChief Executive Officer Feb 2018
-
Ms Ancila Desai Chief Financial OfficerJoint Company Secretary Jun 2020
-
Ancila Desai Chief Financial OfficerJoint Company Secretary
-
Daniel Broadhurst Head of Quality
-
David Sparling Joint Company SecretaryChief Executive Officer
-
Jim Sosic Vice President Operations Supply and Infrastructure
-
Danielle Savaglio Vice President People and Change
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
UBS Nominees Pty Ltd 28,140,173 11.76%
Citicorp Nominees Pty Limited 16,214,169 6.78%
I'Rom Group Co Ltd 15,793,001 6.60%
HSBC Custody Nominees (Australia) Limited 12,006,448 5.02%
One Managed Invt Funds Ltd 11,414,315 4.77%
Brispot Nominees Pty Ltd 8,981,173 3.75%
National Nominees Limited 8,183,784 3.42%
Graeme Leslie Blackman 7,029,710 2.94%
CS Fourth Nominees Pty Limited 6,286,074 2.63%
Jamplat Pty Ltd 5,303,927 2.22%
Mr Anthony John Huntley 5,070,044 2.12%
Paulene Blackman 4,457,737 1.86%
Belgravia Strategic Equities Pty Ltd 3,999,791 1.67%
Mr Rodney Bruce Ebsworth 3,750,000 1.57%
Picherit'S Farm Pty Ltd 3,200,000 1.34%
Mr Anthony Huntley 2,766,338 1.16%
Goen Investments Pty Ltd 2,750,000 1.15%
David Sparling 2,561,144 1.07%
Mr Anthony John Huntley i 2,500,000 1.04%
Mr Gavin George Rogers & Ms Kathryn Ann Rogers 2,500,000 1.04%

Profile

since

Note